References
- Cortes J, O'Brien S M, Pierce S, Keating M J, Freireich E J, Kantarjian H M. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995; 86: 2091–2097
- Thomas D A, O'Brien S, Cortes J, Giles F J, Faderl S, Verstovsek S, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004; 104: 1624–1630
- Sancho J M, Ribera J M, Romero M J, Martin-Reina V, Giraldo P, Ruiz E. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases. Haematologica 2006; 91: ECR02
- Bomgaars L, Geyer J R, Franklin J, Dahl G, Park J, Winick N J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 2004; 22: 3916–3921
- Glantz M J, LaFollette S, Jaeckle K A, Shapiro W, Swinnen L, Rozental J R, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17: 3110–3116
- Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, et al. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007; 109: 3214–3218
- Phuphanich S, Maria B, Braeckman R, Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma or solid tumors as part of a phase III study. J Neurooncol 2007; 81: 201–208